Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin.

HOME
>
論文・技術情報
>
Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin.

Discontinuation and primary care visits in nonvalvular atrial fibrillation patients treated with apixaban or warfarin.

アブストラクト	AIM: Nonvalvular atrial fibrillation (NVAF) requires long-term anticoagulation treatment, which may necessitate frequent primary care visits. MATERIALS & METHODS: NVAF patients initiating warfarin or apixaban in 2012-2017 were identified from linked primary (Clinical Practice Research Datalink) and secondary care (Hospital Episode Statistics) data. A propensity score matched Cox regression model compared discontinuation risk. Primary care visits were compared via negative binomial regression. RESULTS: A total of 2695 apixaban users were matched to warfarin patients. Discontinuation risk was lower with apixaban than warfarin (hazard ratio: 0.40; 95% CI: 0.35-0.46). Apixaban patients averaged 12.2 annual primary care visits, versus 17.1 for warfarin users (p < 0.001). CONCLUSION: Apixaban was associated with reduced rates of discontinuation and primary care visits compared with warfarin.
ジャーナル名	Journal of comparative effectiveness research
Pubmed追加日	2019/2/9
投稿者	Ramagopalan, Sreeram V; Graham, Sophie; Carroll, Robert; Raluy-Callado, Mireia; Nordstrom, Beth L; Donaldson, Robert; Colby, Chris; Mehmud, Faisal; Alikhan, Raza
組織名	Centre for Observational Research & Data Sciences, Bristol-Myers Squibb,;Uxbridge, UB8 1DH, UK.;Evidera, Real-World Evidence, London, W6 8DL, UK.;Evidera, Real-World Evidence, Waltham, MA 02541, USA.;Evidera, Real-World Evidence, San Francisco, CA 94111, USA.;Bristol-Myers Squibb, Uxbridge, UB8 1DH, UK.;Department of Haematology, University Hospital of Wales, Cardiff, CF14 4XW, UK.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/30734571/